Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Verapamil SR for Adults with Newly Diagnosed Type 1 Diabetes to Preserve Beta-Cell Function

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Verapamil SR on individuals with newly diagnosed Type 1 Diabetes. Type 1 Diabetes is a condition where the body’s immune system attacks the cells in the pancreas that produce insulin, a hormone that helps control blood sugar levels. The trial aims to see if Verapamil SR, a medication usually used to treat high blood pressure, can help preserve the function of these insulin-producing cells.

Participants in the study will be randomly assigned to receive either Verapamil SR or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for 12 months, during which participants will take the medication or placebo once daily by mouth. The main goal is to observe changes in the body’s ability to produce insulin in response to food intake over this period.

Throughout the study, participants will undergo regular check-ups and tests to monitor their health and the effects of the treatment. These tests will include measuring the levels of a substance called C-peptide, which indicates how well the body is producing insulin. The study will also track other health markers, such as blood sugar levels and insulin requirements, to gather comprehensive data on the potential benefits of Verapamil SR for people with Type 1 Diabetes.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying the diagnosis of type 1 diabetes within the last six weeks and checking for specific diabetes-related antibodies.

    Fasting C-peptide levels are measured to ensure they are at least 100 pmol/L.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either the active medication, Verapamil SR, or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

  3. Step 3

    Medication administration

    The assigned medication, either Verapamil SR 360 mg or placebo, is taken orally once daily. This continues for the duration of the study.

  4. Step 4

    Regular monitoring

    Participants undergo regular monitoring, including mixed meal tolerance tests (MMTT) at baseline, 3, 6, 9, and 12 months to measure C-peptide response.

    Additional tests include monitoring of proinsulin, insulin, and other related markers, as well as tracking changes in HbA1c levels and insulin requirements.

  5. Step 5

    Safety assessments

    Throughout the study, safety assessments are conducted to monitor for any severe hypoglycemic episodes or diabetic ketoacidosis.

    Participants' time in specific blood sugar ranges is also tracked using continuous glucose monitoring (CGM).

  6. Step 6

    Final evaluation

    At the end of the 12-month period, a final evaluation is conducted to assess the primary endpoint, which is the change in stimulated C-peptide response.

    Secondary endpoints, such as changes in HbA1c and insulin requirements, are also evaluated.

Who can join the trial?

6 criteria

  • Must have given written informed consent, which means you agree to participate in the study after understanding all the details.
  • Must be between the ages of 18 and 44 at the time of giving consent.
  • Must have been diagnosed with **Type 1 Diabetes (T1D)** within the last 6 weeks, starting from the date of your first insulin injection.
  • Must have at least one of the following **diabetes-related autoantibodies** present at screening: **GADA**, **IA-2A**, or **ZnT8A**. These are specific proteins in your blood that are often found in people with Type 1 Diabetes.
  • Must have **fasting C-peptide levels** of at least 100 pmol/L measured at screening. **C-peptide** is a substance made in the pancreas, and its level can help show how much insulin your body is making.
  • Must be willing to follow an intensive diabetes management plan, which means carefully managing your diabetes with the help of healthcare professionals.

Who cannot join the trial?

4 criteria

  • Individuals who do not have **Type 1 Diabetes** cannot participate. **Type 1 Diabetes** is a condition where the body does not produce insulin, a hormone needed to control blood sugar levels.
  • Participants must be within a specific age range, which is not specified here, but generally means that very young children or older adults might not be eligible.
  • Both **male** and **female** participants are considered, so gender is not a reason for exclusion.
  • Participants who are part of a **vulnerable population** are not excluded. A vulnerable population might include groups like pregnant women or people with certain disabilities, but this study does not exclude them based on that status.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Verapamil SR is a medication being studied for its potential to help preserve the function of beta cells in people who have recently been diagnosed with type 1 diabetes. Beta cells are important because they produce insulin, which helps control blood sugar levels. In this trial, Verapamil SR is taken by mouth once a day to see if it can help maintain the body's ability to produce insulin over time.

What is already known about the treatment

Verapamil SR – This medication is administered orally in a sustained-release form, taken once daily. It is currently being studied in clinical trials for its potential to preserve beta-cell function in individuals newly diagnosed with Type 1 diabetes. Verapamil SR is primarily used to treat high blood pressure and certain heart conditions, but its role in diabetes is under investigation. It works by blocking calcium channels, which can affect insulin secretion and beta-cell survival. Verapamil belongs to the pharmacological class of calcium channel blockers.

Investigated diseases

Type 1 Diabetes Mellitus – This is a chronic condition where the pancreas produces little or no insulin, a hormone needed to allow sugar (glucose) to enter cells to produce energy. It typically appears in childhood or adolescence, but it can develop in adults as well. The disease progresses as the immune system mistakenly attacks and destroys insulin-producing cells in the pancreas. Over time, this leads to high blood sugar levels, which can cause various symptoms such as increased thirst, frequent urination, hunger, fatigue, and blurred vision. Managing blood sugar levels is crucial to prevent complications. Regular monitoring and lifestyle adjustments are often necessary to manage the condition effectively.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-506545-27-01Protocol codeVer-A-T1DEstimated enrolment120 patientsSponsorMedical University Of Graz

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.